|
|
12481 High Bluff Drive, Suite 150
San Diego, CA 92130 USA
phone:858-480-2420
fax:877-393-3519
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.calixainc.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Calixa developshospital-based antibiotics to treat infections resulting from resistant strains of bacteria. |
|
| Management |
| Eckard Weber, M.D., President and CEO; James (Yigong) Ge, Ph.D., M.D., Executive Vice President and CSO; Ian Friedland, M.D., Chief Medical Officer; Lynne R. Rollins, CFO. |
| |
|
|
|
|
|
| Keywords |
| antibiotics, resistant, infections, bacteria |
|
|
|
| Description |
|
A biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community.
Calixa's lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a b-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
